Delivette Castor is Assistant Professor (in Medicine), Department of Medicine, Division of Infectious Diseases, the Columbia University Medical Center. She is an epidemiologist who studies how to deliver public health innovations at scale by examining the unique and joint effects of biomedical, behavioral and structural factors that affect infectious diseases in priority populations in low- and middle-income country settings (LMICS), and in marginalized populations in the US. She joined the faculty of Columbia University Irving Medical Center (CUIMC) in November 2019. Prior, she led implementation research activities within the President's Plan for AIDS Relief (PEPFAR) at two U.S government agencies; as Senior Epidemiologist and eventually, acting chief of Implementation Science branch, the office of HIV/AIDS (OHA), United States Agency for International Development (USAID); and Senior Epidemiologist in the Office of Research and Science, the office of the Global AIDS coordinator, Department of State (S/GAC). She worked within PEPFAR-supported programs to design, implement and evaluate comprehensive HIV interventions, introduce and scale-up novel prevention technologies. These often involved designing large community trials utilizing quantitative and qualitative methods, stakeholder engagement, capacity building, analysis, dissemination and utilization of study findings through coordination with policymakers and program-planners. Her HIV research involves intersecting areas of interest such as women's and reproductive health, health disparities, mental health, nutrition, cervical cancer and other emerging infections (i.e., SARS-CoV-2).
BSc, 1997, University of the Virgin Islands
MPH, 2000, University of Alabama at Birmingham
PhD, 2006, Columbia University
MSc, 2009, The Rockefeller University
Areas of Expertise
Implementation Science, Intervention Studies, Disparities / Inequalities in Health, Global Health Diplomacy, Global Health
Settergren SK, Mujaya S, Rida W, Kajula LJ, Kamugisha H, Kilonzo Mbwambo J, Kisanga F, Mizinduko MM, Dunbar MS, Mwandalima I, Wazee H, Prieto D, Mullick S, Erie J, Castor D. Cluster randomized trial of comprehensive gender-based violence programming delivered through the HIV/AIDS program platform in Mbeya Region, Tanzania: Tathmini GBV study. PLoS One. 2018 Dec 6;13(12):e0206074. doi: 10.1371/journal.pone.0206074. PMID: 30521530; PMCID: PMC6283609.
Castor D, Meyers K, Allen S. The only way is up: priorities for implementing long-acting antiretrovirals for HIV prevention and treatment. Curr Opin HIV AIDS. 2020 Jan;15(1):73-80. doi: 10.1097/COH.0000000000000601. PMID: 31688333; PMCID: PMC6903331.
Pretorius C, Schnure M, Dent J, Glaubius R, Mahiane G, Hamilton M, Reidy M, Matse S, Njeuhmeli E, Castor D, Kripke K. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries. J Int AIDS Soc. 2020 Feb;23(2):e25451. doi: 10.1002/jia2.25451. PMID: 32112512; PMCID: PMC7048876.
Miller EH, Zucker J, Castor D, Annavajhala MK, Sepulveda JL, Green DA, Whittier S, Scherer M, Medrano N, Sobieszczyk ME, Yin MT, Kuhn L, Uhlemann AC. Pretest Symptom Duration and Cycle Threshold Values for Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-Transcription Polymerase Chain Reaction Predict Coronavirus Disease 2019 Mortality. Open Forum Infect Dis. 2021 Jan 4;8(2):ofab003. doi: 10.1093/ofid/ofab003. PMID: 33604401; PMCID: PMC7798567.
Laracy J, Zucker J, Castor D, McMahon DJ, Guo TW, Yan M, Shalev N, Scherer M, Gordon P, Sobieszczyk M, Yin MT. HIV-1 Infection Does Not Change Disease Course or Inflammatory Pattern of SARS-CoV-2-Infected Patients Presenting at a Large Urban Medical Center in New York City. Open Forum Infect Dis. 2021 Jan 28;8(2):ofab029. doi: 10.1093/ofid/ofab029. PMID: 33604406; PMCID: PMC7880266.
Phillips AN, Cambiano V, Johnson L, Nakagawa F, Homan R, Meyer-Rath G, Rehle T, Tanser F, Moyo S, Shahmanesh M, Castor D, Russell E, Jamieson L, Bansi-Matharu L, Shroufi A, Barnabas RV, Parikh UM, Mellors JW, Revill P. Potential Impact and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance. J Infect Dis. 2021 Apr 23;223(8):1345-1355. doi: 10.1093/infdis/jiz667. PMID: 31851759; PMCID: PMC8064039.
Shoucri SM, Purpura L, DeLaurentis C, Adan MA, Theodore DA, Irace AL, Robbins-Juarez SY, Khedagi AM, Letchford D, Harb AA, Zerihun LM, Lee KE, Gambina K, Lauring MC, Chen N, Sperring CP, Mehta SS, Myers EL, Shih H, Argenziano MG, Bruce SL, Slater CL, Tiao JR, Natarajan K, Hripcsak G, Chen R, Yin MT, Sobieszczyk ME, Castor D, Zucker JE. Characterising the long-term clinical outcomes of 1190 hospitalised patients with COVID-19 in New York City: a retrospective case series. BMJ Open. 2021 Jun 2;11(6):e049488. doi: 10.1136/bmjopen-2021-049488. PMID: 34083350; PMCID: PMC8182750.